Nitric oxide synthase gene therapy - MaxCyte/Northern Therapeutics

Drug Profile

Nitric oxide synthase gene therapy - MaxCyte/Northern Therapeutics

Alternative Names: eNOS transfected EPCs - Northern Therapeutics; Pulmonary hypertension gene therapy - MaxCyte/United Therapeutics

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MaxCyte; Northern Therapeutics
  • Class Gene therapies
  • Mechanism of Action Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension in Canada (Intrapulmonary)
  • 28 Sep 2017 Phase-II clinical trials in Pulmonary arterial hypertension in Canada (IV) (NCT03001414)
  • 19 Dec 2016 Northern Therapeutics and Ottawa Hospital Research Institute plan the phase II SAPPHIRE trial for Pulmonary arterial hypertension (Adjunctive treatment) in Canada (IV) (NCT03001414)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top